Get the Stockscreener App
4.09
5.98%
-0.26
Design Therapeutics Inc stock is traded at $4.09, with a volume of 7,959.
It is down -5.98% in the last 24 hours and up +15.54% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$4.35
Open:
$4.35
24h Volume:
7,959
Relative Volume:
0.09
Market Cap:
$232.75M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-3.4083
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
+5.68%
1M Performance:
+15.54%
6M Performance:
-4.66%
1Y Performance:
+0.25%
1-Day Range:
$4.0887
$4.35
1-Week Range:
$3.77
$4.415
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.10 | 230.48M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.34 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.20 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.01 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
What MACD and RSI say about Design Therapeutics Inc.Fundamental Forecast for Undervalued Stocks - Newser
Market reaction to Design Therapeutics Inc.’s recent newsPredictive Model for Intraday Swing Forecast - Newser
What technical models suggest about Design Therapeutics Inc.’s comebackAlgorithmic Prediction of Market Breakouts - Newser
What makes Design Therapeutics Inc. stock price move sharplyTrend Analysis for Safer Market Entries - Newser
Using flow based indicators on Design Therapeutics Inc.Chart Based Entry Tool for ROI Traders - Newser
Can momentum traders help lift Design Therapeutics Inc.Free Entry Plan for Oversold Reversal Stocks - Newser
Design Therapeutics, Inc. shares rise 1.26% intraday as Cartesian Therapeutics reports strong clinical trial progress and global expansion. - AInvest
Can Conifer Holdings Inc. hit a new high this monthFree Fast Exit and Entry Strategy Guide - Newser
Trend analysis for Design Therapeutics Inc. this weekFree Capital Growth With Controlled Risk Picks - Newser
Design Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayReal Time Growth Signal with Smart Setup - Newser
Fuchs Dystrophy Pipeline 2025: In-depth Clinical Trials - openPR.com
Measuring Design Therapeutics Inc.’s beta against major indicesPredictable Return Strategy with AI Support - Newser
Technical analysis overview for Design Therapeutics Inc. stockIntraday Price Forecast Using Volume Models - Newser
News impact scoring models applied to Design Therapeutics Inc.Consistent Profit Signals with AI Models - Newser
What are the latest earnings results for Design Therapeutics Inc.Capitalize on momentum-driven investment opportunities - Jammu Links News
How Design Therapeutics Inc. stock performs during market volatilityRisk-Managed Strategy Based on Price Analysis - Newser
What analysts say about DiaMedica Therapeutics Inc. stockDiscover hidden gems in the stock market - Jammu Links News
How does Design Therapeutics Inc. generate profit in a changing economyBuild wealth with reliable stock picks - Jammu Links News
Design Therapeutics Inc. Stock Analysis and ForecastBuild wealth steadily with smart trading - Jammu Links News
How volatile is Design Therapeutics Inc. stock compared to the marketMaster stock selection with insider knowledge - Jammu Links News
What is the dividend policy of Design Therapeutics Inc. stockHigh-yield investments - Jammu Links News
What makes Design Therapeutics Inc. stock attractive to long term investorsLow-Risk Reversal Pattern Analysis Tracker - Newser
Design Therapeutics (DSGN) Expected to Announce Earnings on Monday - Defense World
How many analysts rate Design Therapeutics Inc. as a “Buy”Advanced Screener Alerts That Work - jammulinksnews.com
Has Design Therapeutics Inc. found a price floorFree Stock Selection With High Accuracy - Newser
What are the technical indicators suggesting about Design Therapeutics Inc.Free Stock Insights From AI Tools - Jammu Links News
Key metrics from Design Therapeutics Inc.’s quarterly dataTrend Following Ideas with Volume Confirmation - Newser
Using data filters to optimize entry into Tenax Therapeutics Inc.Pattern Recognition Based Market Move Prediction - Newser
How to build a dashboard for Design Therapeutics Inc. stockTechnical Analysis of Growth Stock Opportunities - Newser
Is it the right time to buy Design Therapeutics Inc. stockExpert Picks Guidance For 2025 - jammulinksnews.com
Backtesting results for PDFS trading strategiesStock Market Trend and Pattern Analysis - Newser
What institutions are buying INEO stock nowMomentum Entry Alerts with Risk Control - Newser
Design Therapeutics Inc. Could See a Relief Rally From SupportSwing Trading Plan With Smart Signals in Review - metal.it
Price momentum metrics for Galectin Therapeutics Inc. explainedTechnical Reversal Setup with Risk Limits - Newser
Evaluating Design Therapeutics Inc. with trendline analysisLow Risk Stock Trade Opportunity Analysis - Newser
Can swing trading help recover from MRVL lossesHigh Return Idea With Technical Filter - Newser
Published on: 2025-07-29 21:50:09 - metal.it
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):